Fc Variants and IL-8 Antibodies Patent Grant

USPTO granted patent US12595299B2 to Chugai Seiyaku Kabushiki Kaisha for Fc region variants and IL-8 antibodies. The patent covers molecules with ion concentration-dependent antigen binding, Fc variants with reduced pre-existing anti-drug antibody binding, and novel IL-8 antibodies optimized for therapeutic applications. The application (No. 17494199) was filed on October 5, 2021, and contains 17 claims under CPC classification C07K 16/00.

For pharmaceutical companies and biotechnology firms developing antibody therapeutics, this patent establishes Chugai's intellectual property rights in Fc engineering technology and IL-8 targeting. Competitors working with similar Fc modification approaches or IL-8 antibodies should conduct freedom-to-operate analyses and consider licensing discussions with Chugai Seiyaku.